BiotechTube

cAd3-Marburg + cAd3-EBO-S

Phase 1Completed
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ebola Virus Disease

Conditions

Ebola Virus Disease, Marburg Virus Disease

Trial Timeline

Jan 6, 2021 → Dec 14, 2021

NCT ID
NCT04723602

About cAd3-Marburg + cAd3-EBO-S

cAd3-Marburg + cAd3-EBO-S is a phase 1 stage product being developed by ICON plc. for Ebola Virus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04723602. Target conditions include Ebola Virus Disease, Marburg Virus Disease.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04723602Phase 1Completed

Competing Products

20 competing products in Ebola Virus Disease

See all competitors
ProductCompanyStageHype Score
Ad26.ZEBOV vaccineJohnson & JohnsonPhase 2
52
rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)MerckPhase 1/2
41
V920 VaccineMerckPhase 1
33
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)MerckPhase 2
52
rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved
85
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus VaccineMerckPhase 2
52
V920MerckPhase 1
33
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
77
BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved
85
V920MerckPhase 1
33
GS-5734Gilead SciencesPhase 2
51
REGN3470-3471-3479Regeneron PharmaceuticalsPre-clinical
22
Ervebo + InmazebRegeneron PharmaceuticalsPhase 2
51
AVI-7537United TherapeuticsPhase 1
30
Placebo + AVI-6002United TherapeuticsPhase 1
30
Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3
74
CMX001Jazz PharmaceuticalsPhase 2
49
BrincidofovirJazz PharmaceuticalsPhase 2
49
Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M AdjuvantNovavaxPhase 1
28
TKM-100802 for Injection + PlaceboArbutus BiopharmaPhase 1
28

Other Products from ICON plc.

JatenzoApproved
82
VAS203 + SalinePhase 3
74
BT524 (Part I) + BT524 (Part II)Phase 3
74
CureXcell® + Sham injectionPhase 3
74
EcN-Suspension + PlaceboPhase 3
74